{"id":"W2474212125","doi":"10.1200/jco.2015.33.15_suppl.8002","title":"Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Clinical endpoint; Erlotinib; Lung cancer; Oncology; Progression-free survival; Gefitinib; Chemotherapy; Gastroenterology; Cancer; Randomized controlled trial; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00199274,0.0008972381,0.001680203,0.0004063439,0.0002190359,0.0007764495,0.0006537224,0.001149408,0.003505202],"category_scores_gemma":[0.001303535,0.0003480482,0.001769646,0.0004035475,0.0005454544,0.0009378059,0.0003867379,0.001942037,0.0005617702],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008119851,"about_ca_system_score_gemma":0.0008194771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005958919,"about_ca_topic_score_gemma":0.001943661,"domain_scores_codex":[0.999374,0.0003612864,0.00005042689,0.00008075604,0.00004097403,0.00009261569],"domain_scores_gemma":[0.999206,0.0002388935,0.0001879042,0.0000547846,0.00003321723,0.000279119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9606227,0.005046075,0.002261804,0.0003727723,0.001127343,0.000043409,0.00005418751,0.0008547495,0.003281803,0.00008580126,0.0007549413,0.02549448],"study_design_scores_gemma":[0.6092076,0.3725659,0.0110371,0.00006641875,0.001860988,0.0001760844,0.00006367864,0.001598715,0.001642126,0.0002839206,0.001465654,0.00003182194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945238,0.002529884,0.0002193734,0.0003001821,0.0001319791,0.0005636407,0.0006228085,0.00003435169,0.001073977],"genre_scores_gemma":[0.9957634,0.001246577,0.0003516943,0.0002682678,0.000130227,0.0005718187,0.0006502686,0.000008157245,0.001009539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003505202,"threshold_uncertainty_score":0.01172608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05094511092598868,"score_gpt":0.436446730433968,"score_spread":0.3855016195079793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}